Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line dovitinib for advanced clear cell renal cell carcinoma
ACTRN12612000140853Phase 2Completed
- Sponsor
- Auckland District Health Board
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in renal cell carcinoma (RCC), sponsored by Auckland District Health Board. Primary endpoint: Progression-free survival. Started Mar 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12612000140853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000140853.